| HOME >> MEDICINE >> TECHNOLOGY |
- Zometa when added to hormone therapy, following surgery, significantly
reduced the risk of cancer returning or death by 36% beyond clinical
benefits achieved with hormone therapy alone(1)
- Findings may allow clinicians to improve standard of care for premenopausal women diagnosed with hormone-sensitive, early-stage breast
cancer - These are the first data from a large clinical program exploring the direct anticancer effect of Zometa in breast, lung and prostate cancer
EAST HANOVER, N.J., May 31 /PRNewswire/ -- New data presented today
showed that Zometa(R) (zoledronic acid) offered a significant anticancer
benefit for premenopausal women with hormone-sensitive, early-stage breast
cancer. The study found that Zometa when added to hormone therapy,
following surgery, significantly reduced the risk of cancer returning or
death by 36% beyond clinical benefits achieved with hormone therapy alone.
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/novartis/33472/
Investigators from the Austrian Breast & Colorectal Cancer Study Group (ABCSG) announced the findings during a plenary presentation today at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, USA.
"This study is the first large-scale trial to demonstrate the significant antitumor benefit of zoledronic acid," said lead investigator Michael Gnant, M.D., of the Medical University of Vienna. "These new findings may allow oncologists to further improve the standard of care for premenopausal women with hormone-sensitive breast cancer."
According to the World Health Organization (WHO), each year
approximately 500,000 women die worldwide because their breast cancer has
returned or spread(2). Moreover, the incidence of breast cancer has been
rising in recent
'/>"/>
| SOURCE Novartis Copyright©2008 PR Newswire. All rights reserved |